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INTRODUCTION 
 
 
The prevalence of diabetes is increasing world over and is expected to affect 57 
million adults in india by 2025. 
Apart from kidney, eye, heart and blood vessels, liver is also indirectly related 
with diabetes mellitus. Virtually the entire spectrum of liver disease is seen in 
patients with type 2 diabetes. This includes abnomal liver enzymes, non alcoholic 
fatty liver disease (NAFLD), cirrhosis, hepatocellular carcinoma, and acute liver 
failure. In addition, there is an unexplained association of diabetes with 
hepatitisC. 
 Finally, the prevalence of diabetes in cirrhosis is 12.3–57% . Thus, patients with 
diabetes have a high prevalence of liver disease and patients with liver disease 
have a high prevalence of diabetes 
 
NAFLD 
 
 Ludwig introduced the term Nonalcoholic steatohepatitis (NASH) to describe a 
form of liver disease that is histologically indistinguishable from alcoholic 
hepatitis but occurs in people who do not consume excess ethanol.1 There is 
renewed interest in Non alcoholic fatty liver (NAFL) recently because of its 
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increased prevalence in diabetes. It has been shown to be a predisposing factor 
for insulin resistance and hyperinsulinemia, a major cause of cryptogenic 
cirrhosis and may even lead to hepatocellular carcinoma.2,3,4  
 
 Nearly 70-80% of the diabetic subjects have been reported to have hepatic fat 
accumulation, referred to as NAFLD.5 There are not enough studies done on the 
hepatic status of diabetic patients in our country. Hence this study aims to 
describe the hepatic profile of type 2 diabetic patients.  
NAFLD represents a spectrum of diseases from simple fatty liver (steatosis), to 
steatosis with inflammation, necrosis, and possible cirrhosis, that occurs in people 
who drink little or no alcohol.  
NAFLD affects more women than men and can be found in all age groups 
diabetes, by most estimates, is now the most common cause of liver disease in the 
U.S. Cryptogenic cirrhosis, of which diabetes is, by far, the most common cause, 
has become the third leading indication for liver transplantation  
.The  liver helps maintain normal blood glucose concentration in the fasting and 
postprandial states. Loss of insulin effect on the liver leads to glycogenolysis and 
an increase in hepatic glucose production.  So Insulin resistance is the main 
culprit in the pathogenisis of  fatty liver 
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. The precise genetic, environmental, and metabolic factors and sequence of 
events that lead to the underlying insulin resistance, however, is not fully 
understood. 
Despite down-regulation of the insulin receptor substrate-2-mediated insulin 
signaling pathway in insulin-resistant states, the up-regulation of SREBP-
1c(sterol regulatory element protein 1 c) and subsequent simulation of de novo 
lipogenesis in the liver leads to increased intracellular availability of triglycerides, 
promoting fatty liver. This also increases VLDL assembly and deposition in liver. 
. The insulin-resistant state is also characterized by an increase in pro 
inflammatory cytokines such as tumor necrosis factor- (TNF-), which may also 
contribute to hepatocellular injury.  
.  
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AIM  OF STUDY 
 
This study aims to describe clinical, biochemical, sonological profile of hepatic 
status in type 2 diabetes mellitus in tertiary care setting in relation with non 
alcoholic fatty liver disease (NAFLD) 
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RIVEW OF LITERATURE 
The Role of the Liver in Glucose Homeostasis 
An appreciation of the role of the liver in the regulation of carbohydrate 
homeostasis is essential to understanding the many physical and biochemical 
alterations that occur in the liver in the presence of diabetes and to understanding 
how liver disease may affect glucose metabolism. The liver uses glucose as a fuel 
and also has the ability to store it as glycogen and synthesize it from 
noncarbohydrate precursors (gluconeogenesis). Mann and Magath demonstrated 
that a total hepatectomy in a dog results in death within a few hours from 
hypoglycemic shock , underscoring the important role the liver plays in 
maintaining normoglycemia. 
Glucose absorbed from the intestinal tract is transported via the portal vein 
to the liver. Although the absolute fate of this glucose is still controversial, some 
authors suggest that most of the absorbed glucose is retained by the liver so that 
the rise in peripheral glucose concentration reflects only a minor component of 
postprandial absorbed glucose. Therefore, it is possible that the liver plays a more 
significant role than does peripheral tissue in the regulation of systemic blood 
glucose levels following a meal, suggesting  that most absorbed glucose is not 
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taken up by the liver but is rather metabolized via glycolysis in the peripheral 
tissues.   
Many cells in the body, including fat, liver, and muscle cells, have specific 
cell membrane insulin receptors, and insulin facilitates the uptake and utilization 
of glucose by these cells. Glucose rapidly equilibrates between the liver cytosol 
and the extracellular fluid. Transport into certain cells, such as resting muscle, is 
tightly regulated by insulin, whereas uptake into the nervous system is not 
insulin-dependent. Glucose can be used as a fuel or stored in a macromolecular 
form as polymers: starch in plants and glycogen in animals. Glycogen storage is 
promoted by insulin, but the capacity within tissues is physically limited because 
it is a bulky molecule. 
Glucose can be used as a fuel or stored in a macromolecular form as 
polymers: starch in plants and glycogen in animals. Glycogen storage is 
promoted by insulin, but the capacity within tissues is physically limited because 
it is a bulky molecule. Insulin is metabolized by insulinase in the liver, kidney, 
and placenta. About 50% of insulin secreted by the pancreas is removed by first-
pass extraction in the liver. Insulin promotes glycogen synthesis (glycogenesis) in 
the liver and inhibits its breakdown (glycogenolysis). It promotes protein, 
cholesterol, and triglyceride synthesis and stimulates formation of very-low-
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density lipoprotein cholesterol. It also inhibits hepatic gluconeogenesis, 
stimulates glycolysis, and inhibits ketogenesis. The liver is the primary target 
organ for glucagon action, where it promotes glycogenolysis, gluconeogenesis, 
and ketogenesis . The formation of glucose from lactate and various 
noncarbohydrate precursors is known as gluconeogenesis and occurs mainly in 
the liver and kidneys. 
  The liver, kidney, intestine, and platelets contain the enzyme glucose-6-
phosphatase, which produces glucose from glucose-6-phosphate and is the final 
step in the production of glucose via gluconeogenesis. This enzyme is absent in 
other tissues. Glucose that is metabolized peripherally may therefore be 
converted back to glucose or to hepatic glycogen via gluconeogenesis with 
lactate as the primary substrate, this is known as Cori cycle. 
In type 2 diabetes, excessive hepatic glucose output contributes to the fasting 
hyperglycemia. Increased gluconeogenesis is the predominant mechanism 
responsible for this increased glucose output, while glycogenolysis has not been 
shown to be increased in patients with type 2 diabetes . Hyperglucagonemia has 
been shown to augment increased rates of hepatic glucose output, probably 
through enhanced gluconeogenesis 
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Key signaling pathways involved in glucose homeostasis in the liver 
 
                  Binding to the glucagon receptor on hepatocytes activates the 
serine/threonine kinase , this kinase causing phosphorylation and activation of 
glycogen phosphorylase  kinase (GPK)  and subsequently glycogen 
phosphorylase (GP), thus activating glycogenolysis. An increase in intracellular 
cyclic AMP also induces gluconeogenesis enzymes  (phosphoenolpyruvate 
carboxykinase [PEPCK] and glucose-6-phosphatase [G6Pase]) via   induction of 
peroxisome  proliferator activated receptor-γ co activator 1α (PGC-1α)  It should 
be emphasized, however, that under fasting conditions (potentially  
hypoglycemic conditions, in particular), non-hormonal mechanisms (principally 
hepatic auto regulation by glucose itself) are capable of supplying a significant 
proportion (up to 50%) of  the body’s glucose requirements via enhancement of 
both glycogenolysis, glucose cycling  and eventually gluconeogenesis) . 
The pathways involved in insulin signalling in the liver are highly complex 
involving hundreds of signaling molecules38,39  ,and thus a myriad of potential 
points for modulation and interaction with other pathways, such as those 
involved in  glucose auto regulation. Insulin signaling  processes also appear to 
differ in different tissues. 
17 
 
                The first key component in the signaling  process is the insulin receptor 
itself and the associated intracellular insulin receptor substrate (IRS) proteins39 . 
The IRS-2 subtype appears to play a more prominent role in the liver, whereas 
the IRS-1 subtype may be more important in skeletal muscle40  and these two 
proteins have different capacities to interact with downstream signaling 
elements41. Within the liver, IRS-1 has been more closely linked with glucose 
homeostasis, whereas IRS-2 may be more closely linked with lipid  metabolism42  
although surprisingly, liver-specific knockout of  IRS 2 in mice does not appear 
to impair hepatic glucose and lipid metabolism43  
                The second key component   involves the activation of the phosphatidyl 
inositol 3-kinase (PI3K) pathway, which appears to be crucial for insulin’s 
metabolic actions in vivo in the liver.44  After PI3K activation, the specific 
regulation of glucose and lipid homeostasis by insulin in the liver diverges  PI3K 
dependentactivation of  Akt (also known as protein kinase B  [PKB])  appears to 
regulate factors involved in gluconeogenesis, whereas PI3K-dependent activation 
of atypical forms of  protein kinase C appears to regulate factors involved in 
lipogenesis  . For instance, pathway downstream of  Akt  leads to inactivation of 
phosphorylase, activation of glycogen synthase, and stimulation of glycogen 
synthesis, thus counteracting the effects of glucagon  
18 
 
In addition to acute effects on metabolic processes, insulin can also induce 
changes in genetranscription in the liver down-stream of the PI3K pathway45,46.  
Insulin can influence the expression of over 150 genes — this occurs via key 
transcription factors, such as FOXO1 that  inhibits expression of PEPCK and 
G6Pase and inhibits gluconeogenesis), sterol-response element binding proteins 
(SREBPs) that primarily regulate genes involved in lipid synthesis), and 
specificity protein 1 (Sp1) that regulates genes for insulin receptors and leptin). 
                  Hence the liver may play a much more important role than the 
peripheral tissues in regulating the normal blood glucose. Liver also removes 
about 50% of the insulin secreted by the pancreas during its first pass through the 
liver. 
NON ALCOHOLIC FATTY LIVER DISEASE 
Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of 
liver injury ranging from simple steatosis to steatohepatitis, fibrosis, and 
cirrhosis. Whereas simple steatosis has a benign clinical course, steatohepatitis is 
a recognized cause of progressive liver fibrosis and can develop into cirrhosis. 
NAFLD and nonalcoholic steatohepatitis (NASH) are the two most common 
chronic liver diseases in United States general population with a prevalence of 
20% and 3%, respectively. Hepatic steatosis is frequently associated with obesity, 
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type 2 diabetes, and hyperlipidemia with insulin resistance as a key pathogenic 
factor. 
 
 PREVALENCE AND NATURAL HISTORY  
 
 
       Little is known about the prevalence or natural history of NASH. Biopsy 
evidence is available primarily from the relatively few symptomatic patients. 
Sequential biopsies in patients with NASH are particularly uncommon. If biopsy 
specimens had been obtained, it is often difficult to determine from the 
morphological descriptions whether fatty changes or steatohepatitis had been 
present. Furthermore, NASH may be missed because by the time biopsies are 
done, most fatty changes may have disappeared so that the hepatitis or cirrhosis 
is considered cryptogenic. Nevertheless, some rough estimates can be made. For 
example, in a study of 4613 male Japanese company employees, 534 were 
moderately obese and almost half had hepatic steatosis as judged by computed 
tomography. Twenty-four per cent of these obese patients had abnormal alanine 
aminotransferase (ALT) activities. A subsequent study revealed ultrasonographic 
evidence of fatty livers in 14% of 2574 patients from Okinawa. Fatty change was 
most common in persons between 40 and 49 years of age. Obesity was the 
strongest associated factor in both sexes; however, in males alcohol also was a 
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strongly associated factor48.
 
In an autopsy study NASH was found in 18.5% of 
markedly obese patients and in 2.7% of lean patients.  
As stated, most cases of NASH have been described in women with or 
without diabetes, but recent studies
47 suggest that the condition is also common 
in men and that obesity, hyper lipidaemia and glycemia are not prerequisites. 
Non-alcoholic fatty liver without appreciable inflammation or fibrosis appears to 
be the most common manifestation of NASH, although by strict criteria it is not a 
hepatitis. Thus, in a recent study of 14 patients with obesity and diabetes-related 
NASH and a median follow-up of 11 years (range 7-16 years), none developed 
evidence of progressive liver diseases48  .
 
However, transition from the 
uncomplicated non-progressive fatty liver to slowly progressive NASH may be 
difficult to discern because biopsy samples are often reviewed without the use of 
the tell-tale connective tissue stains and because sampling variations exist, as in 
most other liver diseases.  
The development from NASH to steatohepatitic cirrhosis was clearly 
documented in a study of 47 patients who had been observed for 1.5-21.5 years 
(median 4.5 years); two patients developed cirrhosis that, in one instance, was 
complicated by  hepatocellular carcinoma (HCC). The degree of obesity, hyper 
lipidaemia   and hyperglycaemia did not correlate with the severity of the 
histological changes. Although some studies show progression in NASH to be 
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rare and, if it occurs, very slow, the Mayo Clinic experiences with NASH suggest 
a less favorable scenario. 
NAFLD and associated conditions 
 
NAFLD is associated with various conditions, which may be considered 
while diagnosing it. It is mainly associated with: 
    Obesity (69 - 100%) 
    Diabetes mellitus (36 - 75%) 
    Hyperlipidaemia (20 - 81%) 
These conditions are associated with insulin resistance and metabolic 
syndrome, which is frequently observed with NAFLD. 
Obesity: More than 70% of patients with NASH are obese. Body weight ranging 
from 10 - 40% higher than ideal is associated with 4 - 6 fold higher incidence of 
NAFLD. There is direct correlation between the severity of obesity and 
severity of NAFLD. 
Diabetes: Upto 75% patients with NASH have diabetes mellitus. Obese, middle-
aged females with DM are more likely to have fatty liver changes on 
ultrasonography  
 Hyperlipidaemia: 20 - 80% of patients with NASH have hyperlipidaemia in the 
form of high blood cholesterol level and/or high triglyceride levels. 
Other associated conditions: 
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    Total  parenteral nutrition for prolonged periods. 
    severe insulin resistance. 
    Significant and rapid weight loss in obese subjects. 
    Familial lipid disorders, e.g., aβ-lipoproteinaemia, hypo β- lipoproteinaemia. 
    Limb lipodystrophy. 
    Weber-Christian disease. 
    Drugs: corticosteroids, methotrexate, tamoxifen, 
 
 PROGRESSION OF DISEASE  
The progression from steatosis to steatohepatitis to cirrhosis and, in some 
patients, to hepatocellular carcinoma over a period of many years is well 
established . The prognosis worsens with each stage of disease. Why some 
patients progress while most do not is not known. The only reliable way, to date, 
of determining this progression is liver biopsy, which may have significant 
economic implications (good or bad) for  the management of patients with type 2 
diabetes. 
It is tempting and perhaps deceptively intuitive to think that, in some 
people, simple fatty liver progresses to steatohepatitis and then to fibrosis and 
cirrhosis. However, an equally plausible alternate hypothesis is that individuals 
prone to develop necro inflammatory injury do so as the fat accumulates.           
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In fact, the limited long-term follow-up studies support the latter paradigm more 
than the former.  
The factors that determine whether a patient with NAFLD also develops necro 
inflammatory changes and fibrosis are not known. 
Possibilities include genetics, dietary composition, and concomitant forms of 
other liver disease (e.g., chronic hepatitis C). There may be important racial and 
ethnic predispositions, but these remain poorly characterized at this time. 
Predictors of NASH and advanced fibrosis: 
HAIR score 
 
1. Hypertension 
2. Alanine transaminase (ALT) > 40 IU/l 
3. Insulin resistance (IR) index > 5 
Presence  of 2 or all 3 factors predict NASH.  
BAAT score 
1. Body mass index (BMI) > 28 kg/m2 
2. Age > 50 yrs 
3. ALT > 2-fold rise 
4. TG > 1.7 mmol/l 
Presence of none or only 1 factor rules out the possibility of fibrosis or cirrhosis. 
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PATHOGENISIS 
The pathogenesis of NASH is unknown.  In 1998,James first proposed the‘two 
hit’ hypothesis for pathogenesis  NASH.  Fatty liver,the earliest and most 
prevalent stage of NAFLD  is thought to sensitize the liver to additional necro 
inflammatory insults,  thus promoting  disease progression to steatohepatitis, 
cirrhosis and hepatic failure. A number of factors point to multi factorial nature 
of this disease, including derangement in metabolic parameters, endotoxin-
induced cytokine release and oxidative stress. After absorption from the 
intestines, fat is carried to the adipose tissue for storage in the form of 
triglycerides. It is released as free fatty acids (FFA) when the body is deprived of 
food or under the effect of certain hormones/ drugs (such as epinephrine, 
corticosteroids). FFA  are carried to the liver bound to albumin. After entering 
the hepatocytes they are either oxidized to produce energy. 
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Insulin resistance the first hit in f NAFLD 
This is the first hit hypothesis in the pathogenesis of NAFLD  
The association between the severity of insulin resistance/ presence of 
NIDDM, and the risk of NASH can be explained by peripheral insulin resistance 
increasing the supply of FFA to the liver and by hepatic insulin resistance  
favouring  the development of oxidative stress.  A central abnormality in the 
pathogenesis of steatosis appears to insulin resistance resulting in lipolysis, which 
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increases circulating free fatty acids which are then taken up by the liver as an 
energy source. The fatty acids overload the hepatic mitochondrial ß-oxidation 
system, leading to accumulation of fatty acids in the liver  Indeed, some 
investigators suggest NAFLD to be the hepatic manifestation of the insulin 
resistance syndrome29. NAFLD does not universally progress to NASH, and the 
precise pathogenesis of steatohepatitis is yet to be determined. 
  However, dysregulation of peripheral lipid metabolism seems to be 
important. There is a strong association between non alcoholic fatty liver and 
features of the metabolic syndrome, suggesting a simultaneous insulin resistance 
and decreased sensitivity to leptin.Leptin may have a role in the regulation of fat 
deposition, fibro genesis, and inflammation in patients with NAFLD.6 Obese 
patients with insulin resistance have decreased serum adiponectin and increased 
serum resistin . 
Cytokines and NASH   
Cytokines are attractive candidates for the ‘second hit’ in the pathogenesis 
of NASH. They are capable of producing all the classical histological features of 
NASH, including  hepatocyte death/apoptosis (TNF-a), neutrophil chemotaxis  
(IL-8) and hepatic stellate cell activation (TNF-a, TGF-b)  . There is evidence 
that endotoxin-mediated cytokine release is important in the occurrence of 
hepatic steatohepatitis and that the use of antimicrobial therapy may be able to 
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prevent or reverse its development. In addition, it has been shown that patients 
with NASH had an increased expression of TNF-a mRNA both in their liver and 
adipose tissue compared to obese controls, and this over-expression correlated 
with histological severity.  Lipid metabolism is, in part, regulated by adipokines, 
including tumor necrosis factor (TNF) and adiponectin. TNF-, which interferes 
with insulin signaling thereby favoring steatosis, is elevated in fatty liver disease 
albeit not specific to type 2 diabetes29. TNF- is also pro inflammatory and, thus, 
may  play a role in the pathogenesis of the  inflammation in NASH30 . 
Adiponectin, in contrast to TNF-, is anti lipogenic and anti-inflammatory and, 
thus, may protect the liver from lipid accumulation and inflammation. 
Adiponectin levels are decreased in conditions associated with NAFLD, 
including insulin resistance28 obesity29,type 2 diabetes , and NAFLD29. 
Adiponectin and TNF- therefore have opposing effects. The net effect of 
increased TNF- and decreased adiponectin is prosteatotic and pro inflammatory.  
This low level of adiponectin expression may predispose patients to the 
progressive form of NAFLD  
Oxidative stress and lipid per oxidation   
There is growing evidence implicating FFA in the production of oxidative stress 
within hepatocytes. Increased fatty acid   b-oxidation as well as peroxisomal fatty 
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acid oxidation can both lead to increase in reactive oxygen species generation 
and subsequent lipid per oxidation. In the fasting state, patients with NAFLD 
have increased plasma levels of b-OH butyrate49  
   Under normal conditions, hepatic aerobic metabolism involves a steady-
state production of pro-oxidants such as reactive oxygen species (ROS) and 
reactive nitrogen  species (RNS), which are balanced by a similar rate of their 
consumption by antioxidants.   Imbalance in the pro-oxidant/ antioxidant 
equilibrium in favour of pro-oxidants constitutes the oxidative stress 
phenomenon, a condition that may induce a number of patho physiological 
events in the liver. Hepatotoxicity by oxidative stress may be achieved through a 
direct attack of ROS and RNS on essential biomolecules with loss of their 
biological functions and cell viability .  
Alternatively, ROS may indirectly activate redox sensitive transcription 
factors such as nuclear factor kB (NF-kB)50 or activator protein-1 (AP-1)51 , thus 
triggering the production of cytotoxic, pro inflammatory and/or fibrogenic 
mediators by Kupffer cells and other non parenchymal cells. . These studies 
suggest that chronic oxidative stress may be important in the progression of fatty 
liver Pessayre et al52  have shown that excess fat deposition in the liver is 
associated with lipid per oxidation and the degree of this per oxidation is directly 
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related to the severity of steatosis. The end-products of lipid per oxidation,         
4- hydroxynoneal and  malondialdehyde, covalently bind to hepatic proteins, and 
act as potent agents for neutrophil chemotaxis and stimulating pro-inflammatory 
cytokines. Malondialdehyde also activates hepatic stellate cells to produce 
collagen, leading fibrosis 
Other factor 
In addition to obesity and insulin resistance, some other environmental or 
genetic factor(s) is required for the progression of NASH. Studies in leptin-
deficient ob/ob mice which have  profound  insulin resistance and dramatic 
hepatic steatosis without steatohepatitis or fibrosis, suggests that leptin may in 
fact have a role in promoting hepatic fibrogenesis, directly by an autocrine effect 
on hepatic stellate cells and indirectly by up-regulating the production of TGF-b 
from sinusoidal endothelial cells and Kupffer cells . The association of hepatic 
iron accumulation and NAFLD continues to be debated. While some studies have 
found that 22 to 62% of individuals with fatty liver disease have evidence of iron 
overload, other have failed to show such relationship53  .In another study, a higher 
incidence  of the HFE mutation  (Cys282Tyr)  was reported. 
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 Candidate genes 
NASH and cryptogenic cirrhosis study suggest that genes might play an 
important role in NAFLD. Different types of candidate genes of NAFLD as 
follows: genetic factors related to insulin resistance, FFA supply and lipid 
metabolism.                                                                                                                      
Apo lipoprotein E, a regulator of lipoprotein metabolism, was included and 
considered to be of great importance. Genes associated with the ‘second hit’, 
include (i) genes encoding proteins involved in the severity of oxidative stress 
such as HFE (haemochromatosis  gene), CYP2E1, CYP4A; (ii) genes encoding 
cytokines and their receptors; (iii) genes related to adverse effects of FFA such as 
transcription factors, peroxisome proliferator-activated receptors (PPARs). 
Among these  candidate genes are: (a) leptin and its receptor, which are related to 
obesity, insulin resistance, increased FFA synthesis and reduced FFA oxidation; 
(b) PPAR regulating a variety of genes encoding enzymes involved in FFA 
oxidation and oxidative stress; and (c) PPAR which up regulates  UCP2 (un-
coupling protein C) and inhibits leptin gene expression and macrophage function. 
NASH is now conceptualized as encompassing at least three components 
among the tetrad of steatosis, hepatocellular injury, focal mixed cell-type 
inflammation and fibrosis.  NASH is characterized by zone-3 dominant hepatic 
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steatosis with ballooned hepatocytes and Mallory bodies, zone-3 peri-cellular and 
peri-venular fibrosis with or without bridging fibrosis, and lobular inflammatory 
cell infiltration6  Liver disease has not been associated with type 1 diabetes 
mellitus, which reflects the current understanding that insulin resistance, not 
insufficiency, is associated with this type of liver disease.7,8                    
Further proof for the association of liver disease with diabetes comes from the 
Insulin Resistance Atherosclerosis Study (IRAS), which showed that liver 
function markers like the Aspartate aminotransferase (AST) and Alanine 
aminotransferase (ALT) are predictors of incident diabetes9 An Italian study 
showed that 10.5% of the subjects who had elevated AST and ALT had diabetes.9 
A similar study in Cleveland showed that nearly 33% of subjects with NASH had 
diabetes.10 
     There are several histological  stages in the progression of NAFLD to 
cirrhosis. The earliest stage is a simple fatty liver alone. Over time, 
steatohepatitis may become associated with increasing fibrosis. Eventually, 
cirrhosis may develop. Cirrhosis secondary to NASH may also be complicated by 
the development of hepatocellular carcinoma.. 
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CLINICAL FEATURES 
Most patients of NAFLD (45 - 100%) have no symptoms or signs of liver 
disease at the time of diagnosis . 
 In these patients, abnormal liver function tests are often discovered 
incidentally. When symptoms occur, they are non-specific – like 
persistent fatigue (50 - 73%), pruritus (0 - 6%), oedema (2 - 10%), malaise, and 
right upper quadrant discomfort or pain8. 
Other features like GI bleeding (0 - 3%), jaundice (0 - 5%), ascites (0 - 
3%), pruritus, and oedema point towards severe liver disease. Ascites, hepatic 
encephalopathy, and variceal bleeding indicate cirrhosis of liver due to 
progressive NASH. 
When the disease is not advanced, diffuse non-tender smooth 
hepatomegaly is present in 25 - 53% of patients. Such patients are usually obese 
and/or diabetic. 
Advanced disease may present with right hypochondrium tenderness, 
jaundice, palmar erythema, spider angioma, portal hypertension, ascites, varices, 
and splenomegaly. 
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DIAGNOSIS 
 
  Diagnosis of NAFLD is based on two criteria: (i) establishing  the presence 
of a fatty liver or steatohepatitis, and (ii) establishing the nonalcoholic nature of 
the disease  process. Radiologic imaging of the liver with sonography, compute 
tomography (CT), or magnetic resonance imaging (MRI) has an adequate 
threshold for detection of fatty infiltration of the liver, used either singly or in 
combination. Each of these modalities has its own pitfalls and cannot distinguish 
steatosis from steatohepatitis. These methods are also insensitive in detecting 
steatosis of less than 25%  
            Liver biopsy is the gold standard for diagnosis of  NAFLD/NASH for the 
following important reasons: (i) to confirm diagnosis and establish severity of 
fibrosis  and presence of cirrhosis, and (ii) to exclude other coexisting conditions 
that can result in hepatitic steatosis. However, ethical consideration as well as 
inherent risk associated with this procedure limit its widespread applicability. 
            Histological diagnosis of steatohepatitis relies on a constellation of 
lesions that include steatosis (mainly macrosteatosis, occasionally 
microsteatosis), ballooning of hepatocytes  (hepatocyte injury), perisinusoidal 
fibrosis and  a mixed lobular inflammatory infiltrates55. Currently, minimal 
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histological criteria required for diagnosis are the presence  of steatosis and intra 
lobular necrotic inflammatory  reactions54.  
 
 
 
Tri chrome stain shows blue staining fibrosis around swollen hepatocytes. 
 
   The ALT/AST ratio is usually less than one. Imaging studies may help with 
diagnosing fatty infiltration of the liver, but they do not help in distinguishing 
between fatty liver, steatohepatitis, and steatohepatitis with fibrosis.11  
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Grading and stages of NAFLD56 .  
Grade of NAFLD 
        Macro vesicular steatosis 
       Grade 0: No steatosis 
       Grade 1: < 33% steatosis 
       Grade 2: < 33–66% steatosis 
       Grade 3: > 66% steatosis 
     Necro inflammatory activity 
        Grade 1 (mild) steatosis up to 66%; occasional ballooned   hepatocyte  
(mainly zone 3); scattered intra-acinar neutrophil (PMN) lymphocytes, no or mild 
portal inflammation. 
       Grade 2 (moderate) steatosis of any degree; obvious zone 3 ballooning 
degeneration; intra-acinar PMNs; zone-3 peri sinusoidal fibrosis may present 
mild to moderate, portal and intra-acinar inflammation. 
  Grade 3 (severe) pan acinar steatosis; widespread ballooning; intra-acinar 
inflammation; PMNs associated with ballooned hepatocyts, mild to moderate 
portal inflammation. 
 
Stage of NAFLD 
Stage 1: zone 3 perisinusoidal/pericellular fibrosis; focally or extensively present. 
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Stage 2: zone 3 peri sinusoidal/peri cellular fibrosis with focal or 
extensively peri portal fibrosis. 
Stage 3: zone 3 peri sinusoidal/peri cellular fibrosis and portal 
fibrosis with focal or extensive bridging fibrosis. 
Stage 4: cirrhosis 
 
 
TREATMENT STRATEGIES 
 
 
Currently, there are no effective therapies for NASH, as its natural history and 
prognosis are not well understood. Treatment of patients with non-alcoholic fatty 
liver has typically been focused on the management of associated conditions such 
as obesity, diabetes mellitus, and hyper lipidemia as well as discontinuation of 
potentially hepatotoxic drugs 
. Appropriate metabolic control for patients with diabetes mellitus or hyper 
lipidemia is recommended, but is not always effective in reversing  non-alcoholic 
fatty liver associated with obesity may resolve with weight reduction,, although 
the benefits of weight loss have been inconsistent. On the other hand, striking 
weight losses have also been associated with progression of the disease. 
Moderate and gradual weight loss can safely improve in chronic liver disease 
associated with obesity and diabetes. Rapid weight loss may aggravate the 
histological lesions of steatohepatitis . A weight loss of 500 g per week in 
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children and 1600 g per week in adults is recommended, although the most 
appropriate rate of weight loss is still to be established in fatty liver. 
 A number of pharmacologic agents have been shown to be promising in 
the treatment of NASH . Promising results of pilot studies evaluating 
ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine and alpha-
tocopherol suggest that these medications may be of potential benefit in the 
treatment of patients with nonalcoholic fatty liver, but need further study in 
controlled trials.  The association of hyperinsulinemic insulin resistance has 
provided a target for treatment. Metformin, a biguanide that reduces 
hyperinsulinemia and improves hepatic insulin resistance has been shown to 
greatly reduce hepatomegaly and steatosis in mice and may potentially be useful 
in the treatment of NASH in humans. 
 
   Study by Department of clinical biochemistry (2008) by sandya 
Sharma,dharmveer et all in SMS college  Jaipur  showed  that (Indian)  journal 
clinical biochemistry,2008/23)  Subject with NAFLD were more obese, 
dyslipidemic and glucose intolerant. Almost 70% subjects with NAFLD had 
metabolic syndrome which is five and half fold higher than those without 
NAFLD. Results of the present study supports the hypothesis that the insulin 
resistance is a key factor in Metabolic syndrome, plays a pivotal role in the patho 
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physiology of NAFLD57   as subjects with NAFLD were insulin resistant and 
prevalence of NAFLD was significantly higher in those with metabolic 
syndrome.Thus,fatty liver can be considered as hepatic consequence of  
metabolic disease leading to increase prevalence of NAFLD 
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Materials and methods 
 
This study was done at the Diabetology Clinic of Coimbatore Medical College 
and Hospital, Coimbatore.  
One hundred and eighteen type 2 diabetic patients diagnosed according to the 
American Diabetic Association criteria, newly diagnosed or on follow- up were 
included in the study.  
.Random selection was done using random number charts. 
 
 Patients with history of any chronic drug intake other than oral hypoglycemic 
drugs, jaundice or alcohol intake, HBsAg positive were excluded from the study. 
 
 An informed consent was taken. The study protocol was approved by the Ethics 
committee of Coimbatore Medical College Hospital.  
The type of oral hypoglycemic drug intake, height and weight were recorded and 
Body Mass Index (BMI) calculated. 
 Patients were subjected to biochemical investigations to detect the liver enzyme 
levels, serum bilirubin, serum albumin, serum globulin, serum total proteins and 
total cholesterol. Serum albumin levels of 3.5 -5.5 mg%, serum globulin of 2-
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3.5mg%, AST of 0 – 35 IU/L, ALT of 0 – 35 IU/L, Bilirubin levels of 0.3-1 
mg%, total cholesterol less than 200mg%, serum total proteins of 5.5-8mg%,  
fasting glucose less than 130mg% and a 2hr post prandial glucose of less than 
180mg% were taken as normal . Their most recent fasting and post-prandial 
blood glucose values were recorded to asses the control of diabetes.  
Fifty two patients were subjected for ultrasonographic examination by a qualified 
radiologist who was masked from the patient’s diagnosis or the indication for 
ultrasound, to assess the liver parenchyma, liver size, gall bladder, biliary and 
portal system. 
 The echo texture of the liver parenchyma was graded as follows 
Grade 1: A slight diffuse increase in fine echoes in the hepatic parenchyma with 
normal visualization of the diaphragm and intrahepatic vessel borders. 
Grade 2: A moderate diffuse increase in fine echoes with slightly impaired 
visualization of the intrahepatic vessels and diaphragm. 
Grade 3: A marked increase in fine echoes with poor or no visualization of the 
intrahepatic vessel borders, diaphragm and posterior portion of the right lobe of 
the liver.12  
 
We used ultrasonography to detect liver changes since this method is sensitive in 
detecting fatty liver, is cheap, minimally invasive and easy to perform, and 
ensures patient compliance. It has been shown that attenuation coefficient of the 
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liver on ultrasound increases as the amount of fat in the liver increases, though 
the same is not true for fibrosis. However, this method does not allow for 
quantification of fat infiltration.13 
 The data was analyzed and statistical conclusions drawn using the SPSS 13.0 
software.  
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ANALYSIS OF RESULTS  
 
A total of one hundred and eighteen patients were included in the study, 
71(60.2%) females and 47(39.8%) males. The age and sex distribution is shown 
in table no: 1. 
 
Table No: 1 Age and Sex distribution 
Sex 
Age Class 
Female Male 
 30-39 6 85.7% 1 14.3% 
  40-49 16 59.3% 11 40.7% 
  50-59 26 66.7% 13 33.3% 
  60-69 20 52.6% 18 47.4% 
  70-79 3 42.9% 4 57.1% 
  Total 71 60.2% 47 39.8% 
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         Eleven (9.3%) cases were newly diagnosed during the course of the study. 
Sixty six (55.9%) cases had diabetes for duration less than 5 years. Forty one 
(34.7%) cases had diabetes for a duration more than or equal to 5 years. 
 
One hundred and eleven patients were on oral hypoglycemic drugs, 
including 2 patients who were additionally on plain insulin injections. Majority 
of the patients were either on glibenclamide alone or combination of both 
glibenclamide and metformin. Eight patients though diagnosed to have diabetes 
were not on any drugs at the time of presentation. The dosages they were on 
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ranged from 2.5mg to 10 per day for glibenclamide and 500 mg to 3000 mg per 
day for metformin. 
 
 
Fig 1 Type of Antidiabetic treatment 
 
Not on any treatment
Metformin
OHA plus Insulin
Glibenclamide
Glibenclamide &
Metformin
Ty
pe
 o
f t
re
at
m
en
t
50.0%40.0%30.0%20.0%10.0%0.0%
Percent
7.34%
3.67%
0.92%
49.54%
38.53%
 
 
Results of the biochemical investigations are on table. 2 
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Table No: 2   Biochemical  Investigations 
 
Investigation Mean(SD) Maximum Minimum 
STP 7.0(0.4) 7.9 6.0 
Serum Albumin 4.1(0.4) 4.8 2.4 
Serum Globulin 2.9(0.4) 3.7 1.2 
Serum Bilirubin .9(0.3) 2.1 .4 
AST 23(8) 60 12 
ALT 19(8) 55 10 
ALP 114(38) 211 30 
Fasting Blood Glucose 139(46) 250 70 
Post prandial Blood Glucose 210(55) 330 110 
Total Cholesterol 231(34) 328 197 
 
The total serum proteins were within the normal range for all the patients 
with a mean value of 7.03 +/- 0.4.  low albumin levels, taken as less than 3.5 
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mg% were found in 4 (3.4%) patients and low globulin level, taken as less than 2 
mg% in 2 (1.7%) patients. 
 
  Liver function tests revealed an elevated AST levels taken as more than 35 
IU/L in 8 (6.8%) patients and an elevated ALT levels taken as more than 35 IU/L 
in 5 (4.2%) patients. An AST/ALT ratio of more than 1 was found in 101 
(85.6%) patients. Alkaline phosphatase levels were above 120 IU/L in 37 
(31.4%) patients. 
Age-wise and Sex-wise comparison of the liver function tests (Tables 
3&4) revealed no significant difference between the various age classes or 
between sexes. 
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Table No: 3 Age wise comparison of mean value of Liver function tests 
Age class 
Test 
30-39 40-49 50-59 60-69 70-79 
STP 7.0 7.0 7.0 7.1 7.0 
S.Albumin 4.0 4.3 4.0 4.0 4.3 
S. Globulin 2.9 2.9 2.9 2.9 2.9 
S. Bilirubin .9 .9 .8 1.0 1.2 
AST 23 22 22 23 31 
ALT 19 19 19 20 25 
ALP 110 127 110 109 119 
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Table No: 4 Sex wise comparison of Liver function tests 
Sex 
Investigation 
Female Male 
STP 7.0 7.1 
Serum Albumin 4.1 4.2 
Serum Globulin 2.9 3.0 
Serum Bilirubin 0.8 1.0 
AST 22 24 
ALT 19 20 
ALP 114 114 
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Among the patients whose recent fasting and 2 hr post prandial blood 
glucose values were available, 47 percent had a fasting glucose more than 130 
mg% and 61% had a 2 hr post prandial glucose more than 180mg%. There was 
no significant difference between mean values across gender or age classes. 
Body mass index measurements revealed that 25 (35.2%) women were 
over weight (BMI>25) and 5 (7.0%) were obese (BMI>30). The numbers of 
overweight men were 12 (25.5%).  No male patient was found to be obese. 
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Ultra sonographic examination was done in 52 patients, fatty liver was 
found to be more common in females. Overall 23 patients (42.3%) had fatty liver 
out of the 52 patients screened. Sex wise and BMI class wise distribution is given 
in tables 5 & 6. Hepatomegaly was identified in 5 (9.6%) patients of whom 4 
were males. Asymptomatic gall stones were found in 5 (9.6%) patients, 3 females 
and 2 males. Bile duct was found to be dilated (>5mm) in 6 patients, portal vein 
was normal (<12mm) in size in all the patients 
 
 
 
                         Table No: 5 Sex distribution of fatty liver 
 
Sex 
Fatty Liver 
Female (%) Male (%) 
Grade 1 fatty liver 13(50) 8(30.8) 
Grade 2 fatty liver 2(7.7) 0(0) 
No fatty change 11(42.3) 18(69.2) 
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         Table No: 6 BMI Class wise distribution of fatty liver 
BMI Class  
Fatty Liver 
 Underweight Normal Overweight Obese 
Morbid 
Obesity 
Grade 1 fatty liver .0% 25.0% 31.3% 100% .0% 
Grade 2 fatty liver .0% .0% 6.3% .0% .0% 
No fatty change 100.0% 75.0% 62.5% .0% .0% 
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DISCUSSION 
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DISCUSSION 
 
Since clinical symptoms of fatty liver are nonspecific or silent this study does not 
attempt to define the clinical symptoms of fatty liver.  Fatty liver most commonly 
affects middle-aged women with obesity, altered glucose metabolism, hyper 
lipidemia, and hypertension.  
 
Age, Gender and Obesity 
As reported by Kelly et all28 there was no difference in the mean age of 
patients with fatty liver as compared to those with normal liver. Sixty five 
percent of the patients with fatty liver in this study were females but no 
significant difference(p value>0.05) in proportion based on gender was found in 
those with grade 1 fatty liver compared to those without evidence of fatty liver. 
Obesity was found to have a significant association with fatty liver, in the current 
study 70% of patients with grade 1 fatty liver had a BMI more than 25 and both 
patients with grade 2 fatty liver were overweight. 
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Liver enzymes  
Reid etal14 and Dixon et al15  found elevated AST levels in patients with 
NASH. Laboratory abnormalities identified included a 2-4-fold elevation of 
serum amino transferase levels while other liver function test results were 
normal. Agarwal etal16 and Kelly et al28 documented elevation of ALT as the 
biochemical abnormality in patients with NASH.  A recent study found that 
patients with NASH and those with higher grade of histological inflammation 
had increment of transaminases and albumin levels . The same study showed a 
correlation of fibrosis with AST and ALT levels. Elariny etal showed that while 
ALT was associated with NASH and advanced fibrosis, the majority of the 
patients with either NASH or advanced fibrosis had normal AST.13  An 
AST/ALT ratio >1.0 was yet another finding in a study on NASH15.  
Contrary to all these a study in 2003 found liver enzymes to be insensitive 
and unreliable to confirm the diagnosis or stage the extent of fibrosis. Older age, 
obesity, and diabetes were shown to be predictive of fibrosis. 
Our study also did not find a significant elevation of any of the liver 
enzymes. There was no statistically significant difference (p value >0.05) 
between the parameters among patients with grade 1 fatty liver and those without  
fatty liver (table no: 7). Eighty five percent of the patients in this study had 
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AST/ALT ratio more than one, but it was not found to have any association with 
fatty liver. 
 
 
Table No: 7   Liver enzymes in patients with fatty liver 
Enzyme Grade 1 fatty liver Grade 2 fatty liver No fatty change 
AST 22 21 21 
ALT 19 17 18 
AST/ALT 1.2 1.2 1.2 
ALP 121 77 110 
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Insulin resistance   
Obesity, insulin resistance, and increased concentrations of plasma fatty 
acids are considered to increase the risk for fatty liver, and each of these 
metabolic factors is also characteristic of type 2 DM29.   It has been reported that 
fatty liver in turn influences severity of hepatic insulin resistance in type 2 DM. 
Among nonobese men without type 2 DM, fatty liver was found to correlate with 
hepatic insulin resistance independently of obesity and  intra-abdominal 
adiposity28. Volunteers with type 2 DM and fatty liver were substantially more 
insulin resistant than those with  type 2 DM  but without  fatty liver and had 
higher levels of plasma free fatty acids and more severe dyslipidemia30.  The 
present study did not measure insulin resistance but comparing the mean blood 
glucose values between those with or without fatty liver did not reveal any 
significant difference (p value >0.05) (Table no: 8) 
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Table No: 8       Mean Fasting and Post prandial blood glucose in Patients 
with fatty liver 
 
Blood Glucose 
Grade 1 fatty 
liver 
Grade 2 
fatty liver 
No fatty change 
Fasting 
 
132 130 134 
2 Hr Post prandial 186 230 216 
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Hyperlipidemia  
 
 
Fatty acid flux to the liver has been postulated as an important factor in the 
pathogenesis of fatty liver and is also an important determinant of the synthesis 
and secretion of triglyceride-rich lipoproteins29. It is possible, therefore, that 
hepatic steatosis may influence the severity of dyslipidemia in type 2 DM. 
Hypertriglyceridemia is more severe in individuals with fatty  liver.  Only the 
total cholesterol levels were assayed in our study. A comparison of the mean total 
cholesterol levels between the fatty liver group and the rest did not reveal any 
statistically significant difference. 
Treatment 
Patients with diabetes should have their disease controlled appropriately. 
Since NAFLD is associated with insulin resistance, the use of insulin-sensitizing 
agents may be logical. The thiazolidinediones (e.g. pioglitazone) improve 
peripheral insulin sensitivity. A small study of patients treated with troglitazone 
showed improvement in mean ALT levels and in hepatocellular inflammation. 
Metformin has been shown to improve serum aminotransferase levels. 
  However, there are no definitive data on the use of these drugs in the 
treatment of NAFLD12 .The risks of hepatotoxicity associated with these agents 
have not yet been well characterized in this populations  In a recent randomized 
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controlled trial, metformin was found to be superior to vitamin E in terms of 
normalization of ALT31. 
  A significant reduction in all the liver enzymes was observed after 
Essentiale treatment32 Essentiale is prepared from Soya beans, and has 
phosphatidylcholine as its active ingredient. Some studies have explored the 
efficacy of glitazones, vitamin E, probucol, atorvastatin and alternative therapies 
like betaine, and have shown some beneficial results33,34,35,36 
Based on the results of the study by Osei-Hyaiman et al, the hepatic 
Endocannabinoid system may be a target for the treatment of nonalcoholic 
steatohepatitis (NASH)37 
Currently, treatment is focused on modifying risk factors such as obesity, 
diabetes mellitus, and hyperlipidemia. Antioxidants such as vitamin E, N-
acetylcysteine, betaine, and others may be beneficial in the treatment of NASH. 17 
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CONCLUSION 
  
The increasing prevalence of fatty liver in diabetes is well established.  
 
There is an increasing understanding about its aeti pathogenesis, and its various 
pathological stages have been well defined.  
 
It is important to acknowledge that the increased incidence of steatohepatitis and 
hepatic fibrosis in type 2diabetes may translate into increased incidence of hepato 
cellular carcinoma. 
 
 Liver biopsy though the gold standard for the diagnosis and staging of the 
disease, cannot be used for large scale screening. More non invasive methods are 
the need of the hour for early and wide screening to detect this disease. 
 
 Liver enzymes were thought to be a potential non invasive strategy for early 
detection of this disease, but the present study did not find any correlation of the 
level of liver enzymes and the degree of fatty liver in Indian patients. 
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so the conclusion  is less expensive non invasive USG of liver will be the ideal 
diagnostic tool which  is also well trained operator dependant can definitely help 
to detect early fatty liver in patients with diabetes 
 
The moral of study is force is needed for all physicians to study and practice with 
USG as bed side diagnostic tool for management and follows up study of type 2 
diabetes mellitus patients. 
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1 r sumathi 39 f 4571 0 1 1 0 51 152 22.1 7.2 4.1 3.1 1.4 28 24 1.17 103 210 250 168
2 mohammed usuf 60 m 2410 0 0 0 0 7.2 3.6 1.2 25 23 1.09 103 175 211 n n n normal normal
3 muthukumar 65 m 2481 0 0 0 0 57 153 24.3 7.2 0.7 18 16 1.13 67 85 174
4 ramesh 48 m 1009 0 0 1 0 70 172 23.7 7.3 4.5 2.8 1.4 41 39 1.05 131 100 140
5 jayaraj 38 m 2428 0 0 0 0 6.8 1.2 33 29 1.14 200 125 198 1 e n normal normal
6 rukumani 47 f 1044 0 1 0 0 60 148 27.4 7.1 4.3 2.8 0.6 21 18 1.17 74 100 180
7 kalilrahman 55 m 2631 0 1 0 0 7.2 0.7 20 17 1.18 176 120 1 e s normal n
8 kahil rahman 65 m 6542 0 1 0 0 7.2 0.7 20 17 1.18 176 140 210 1 n n normal n
9 jaiburnisa 50 f 3451 0 60 153 25.6 7.7 0.8 23 19 1.21 158 120 250
10 fathima 53 f 3903 0 6.7 0.9 36 27 1.33 195 160 208 n n n n n
11 sivaraj 45 m 1777 0 6.5 1 15 13 1.15 97 204 1 n n n n
12 natarajan 47 m 2235 0 1 0 0 82 170 28.4 6.3 1.1 26 21 1.24 57 86 112 1 e n normal normal
13 padma 42 f 861 0 0 1 0 60 153 25.6 6.9 4.3 2.6 0.7 15 12 1.25 91 90 140
14 sisily 40 f 2528 0 1 0 0 6.8 4 2.8 0.8 21 19 1.11 136
15 bagyam 63 f 7279 0 1 1 0 55 148 25.1 7.8 4.1 3.7 1.2 13 11 1.18 110 170 230 n n n n n
16 arumugham 55 m 2304 1 0 0 0 75 170 26.0 6.9 3.2 1 19 14 1.36 77 n n n normal normal
17 valliammal 60 f 2207 1 1 0 0 250 330
18 vasantha 60 f 2251 1 1 0 0 53 145 25.2 6.2 4.1 2.1 1.5 35 32 1.09 127 110 180
19 gangadaran 43 m 2548 1 1 1 0 45 160 17.6 7.1 4.1 3 1.5 35 32 1.09 125 120 210
20 palanisamy 43 m 2548 1 0 1 0 26 21 1.25 112 113
21 vishalakshi 65 f 2937 1 0 0 0 19 22 1.21 `109
22 moideen 51 m 1246 1 1 0 0 60 167 21.5 7.9 4.5 3.4 0.9 24 15 1.60 108
23 mohana 55 f 6545 1 1 1 0 7 0.9 19 14 1.36 104 180 197 1 n n n n
24 tamilselvi 34 f 3861 1 1 1 0 62 154 26.1 7.1 0.9 19 15 1.27 78 261 1 n n n n
25 baby 58 f 8515 1 1 0 0 80 150 35.6 7.3 4.3 3 0.8 41 38 1.08 104
26 vasantham 30 f 1988 1 0 0 0 43 142 21.3 6.2 3.9 2.3 0.6 18 15 1.20 77 120 240
27 palanisamy 50 m 5266 1 1 1 0 75 170 26.0 7.1 4.1 3 1.2 37 33 1.12 136 230 310
28 soosai 55 m 965 1 1 0 0 55 153 23.5 7.3 4.2 3.1 0.8 17 15 1.13 80 80 150
29 mariappan 62 m 930 1 1 0 0 64 165 23.5 6.8 0.8 18 15 1.20 131 160 290 n n n normal n
30 mahalakshmi 58 f 7412 1 1 0 0 55 152 23.8 7.2 3.9 3.2 0.7 18 15 1.20 103 170 270
31 santhakumar 42 f 3215 1 1 0 0 65 158 26.0 7.2 3.9 3.3 0.6 19 14 1.36 113 130 230
32 shaharvan 36 f 2666 1 1 0 0 60 153 25.6 6.9 3.7 3.2 0.6 18 15 1.20 108 190 250
33 reetha mary 55 f 3214 1 1 1 0 72 155 30.0 7.7 4.2 3.5 0.6 16 10 1.60 72 100 160
34 krishnaveni 60 f 2751 1 1 1 0 84 155 35.0 7 1.5 18 10 1.80 90 90 210 226
35 saroja 61 f 1228 1 1 0 0 58 145 27.6 7.3 0.8 18 15 1.20 76 211 n n n normal n
36 shamuvel 30 f 1265 1 1 1 0 7.1 4.1 3 1 22 17 1.29 129 150 240
37 duraisamy 50 m 2643 1 1 1 0 48 150 21.3 7.4 0.7 19 14 1.36 90 160 206 n n n n n
38 nagaraj 48 m 1779 1 1 1 0 6 0.5 19 17 1.12 104 190 210 1 n n n n
39 senniyappan 61 m 2384 1 1 1 0 6.8 0.6 18 15 1.20 110 210 n n n n n
40 sivabakyam 53 f 2466 2 1 0 0 64 154 27.0 7.1 0.7 18 15 1.20 107 n n n normal normal
41 maruthachalam 60 m 2527 2 1 0 0 64 155 26.6 7.2 4.3 2.9 1.3 60 55 1.09 110 100 130
42 sararthamani 45 f 772 2 1 1 0 52 150 23.1 6.8 4.8 2 1.2 27 25 1.08 163 90 120 n n n normal 9mm
43 saraswathy 65 f 4521 2 1 1 0 7.2 4.3 2.9 0.6 21 17 1.24 166
44 annairaj 47 m 4605 2 1 1 0 6.3 0.8 16 14 1.14 111 252 n n n n n
45 Backiam 60 f 1451 2 1 0 0 55 155 22.9 6.4 4.4 1.2 1.2 54 36 1.50 86 1 n s
46 vasantha 42 f 740 2 1 1 0
47 vasantha 51 f 1890 2 1 1 0 51 156 21.0 7.2 4.1 3.1 0.9 25 22 1.14 67 90 140
48 rajammal 60 f 1635 2 1 1 0 77 164 28.6 6.5 2.4 2.4 1 35 32 1.09 174 200 230
49 chacko 75 m 1143 2 1 0 0 7.3 4.2 3.1 0.9 35 30 1.17 121 n n n distendednormal
50 amernuisa 70 f 3460 2 1 1 0 2 n s normal normal
51 mohd yakoob 65 m 7463 2 1 0 0 7.5 4.6 2.9 0.7 25 21 1.19 90
52 palanisamy 65 m 6517 2 1 0 0 54 155 22.5 7.4 4.5 2.9 1.5 23 19 1.21 122 90 180
53 savitha 52 f 2537 2 1 1 0 63 153 26.9 6.8 0.7 17 19 0.89 74 1 n n normal n
54 padmanaban 60 m 4581 2 1 0 0 75 160 29.3 6.4 3.7 2.7 0.6 14 12 1.17 116 100 190 n n n normal n
55 kalimuthu 54 m 451 2 1 0 0 67 163 25.2 6.6 4.3 2.3 1 17 15 1.13 124 113 260 1 n n normal n
56 badurnisa 45 f 2232 2 1 0 0 75 156 30.8 7.2 4.7 3.1 0.4 15 12 1.25 182 110 190 1 n n 6.6 n
57 kani 48 m 5181 2 1 0 0 80 164 29.7 7.6 4.5 3.1 0.7 20 18 1.11 162 140 250
58 marulamani 60 m 8452 2 1 0 0 80 165 29.4 7.2 4.3 2.9 0.7 31 22 1.41 211 180 270
59 pechiammal 57 f 5797 2 1 0 0 65 155 27.1 7.2 4 3.2 0.8 33 24 1.38 107
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60 rukumani 45 f 1542 2 1 1 0 64 155 26.6 7.2 4 3.1 1.2 46 35 1.31 103 110 170 154 n n n n n
61 sabiya 41 f 2757 2 0 1 0 84 156 34.5 7.2 4 3 0.6 23 17 1.35 177 105 165 223 1 n n normal n
62 thankamma 62 f 5414 3 1 0 0 57 167 22.0 6.6 3.2 4 0.9 18 22 0.82 30 117 188 204 n n n normal
63 sakunthala 56 f 1511 3 1 1 0 6.9 3.9 3 0.6 21 17 1.24 80 154 243 175 n n n n n
64 arumugham 54 m 2467 3 1 1 0 77 170 26.6 7.1 4 3 1 21 25 0.84 112 132 221 128 n n n normal normal
65 kala 59 f 6617 3 1 1 0 67 155 27.9 6 4.1 1.9 0.5 18 12 1.50 67 140 180 163 n n n 5mm 10mm
66 gomathy 50 f 6751 3 1 1 0 58 155 24.1 6.8 3.9 2.9 0.9 15 13 1.15 67 100 180 155 n n n 7mm n
67 chinnasamy 41 m 748 3 1 0 0 50 175 16.3 6.3 3.9 2.4 0.9 18 15 1.20 107 230 330 167
68 chandrika 40 f 6650 3 57 155 23.7 7.6 4.2 3.4 0.8 17 11 1.55 161 110 240 154 n n n normal n
69 selvi 42 f 2352 3 1 0 1 7.3 4 3.3 0.9 21 19 1.11 180 178
70 sundran 66 m 6910 3 1 0 0 60 165 22.0 7.3 4 3.3 0.9 19 16 1.19 95 140 270 145 n n s 6mm n
71 kuthammal 60 f 8261 3 1 1 0 57 153 24.3 7.7 4.2 3.5 0.6 19 17 1.12 95 150 240 231
72 arunachalam 44 m 3265 3 1 1 0 52 165 19.1 7.3 4 3 0.9 23 21 1.10 126 127 120 223 n n n n n
73 subramani 50 m 2963 3 1 0 0 54 164 #### 7.4 4 3 1.1 20 15 1.33 174 132 165 328 n n n n n
74 sebastin 67 m 3688 4 1 0 0 59 171 19.8 7.6 5 3.2 0.9 20 17 1.18 63 87 121 147 n e n 5.5 11.8
75 mary 52 f 2605 4 1 1 0 65 168 20.6 6.4 3.2 2.9 0.9 26 42 0.62 120 190 240 137 1 n s normal n
76 govindaraf 57 m 6523 4 1 0 0 90 175 29.4 7.1 4 3 0.8 21 15 1.40 93 70 122 142 1 n n normal n
77 aysha beevi 45 f 3265 4 1 1 0 68 150 30.2 7.3 4.1 3.2 0.8 21 16 1.31 127 230 210 137
78 jayakumar 60 m 989 5 1 0 0 67 155 27.9 6.6 4.5 2.5 1.6 21 15 1.40 59 154 211 199 n n n normal normal
79 venkatammal 58 f 6380 5 1 0 0 45 145 21.4 7.3 4.2 3.1 0.8 15 12 1.25 69 120 210 211 n n n 6.6mm 11mm
80 lakshman 58 m 2524 5 1 1 0 60 168 21.3 7.3 4 3 0.9 21 19 1.11 67 213 164 n
81 kannmal 45 f 1542 5 1 1 0 67 156 22.0 6.5 4 2.5 1 32 28 1.08 121 123 187 138 n n
82 rajammal 56 f 1939 5 1 0 0 61 170 20.3 7.3 4.3 2.8 0.8 21 17 1.24 100 108 172 147 n n n
83 alagirisamy 56 m 2166 5 54 151 23.7 7.4 4.3 3.1 1.5 29 24 1.21 154 90 180 221 n n
84 marakadam 66 f 6758 5 1 0 0 62 148 28.3 6.4 4.2 2.2 1.1 22 18 1.22 131 110 180 207 n n n normal 11mm
85 lakshmi 70 f 5784 5 1 0 0 7 4 3 0.8 19 16 1.19 121 132 203 179
86 mariammal 50 f 6762 5 1 0 0 26 42 0.62 108 102 176 165
87 lakshmi 55 f 4578 5 1 0 0 6.1 4 2 0.6 17 12 1.42 104 110 150 145 1 n n normal n
88 rajendran 45 m 2712 5 1 0 0 58 162 22.1 7.1 0.8 19 14 1.36 155 140 286 n n n normal n
89 kamala 58 f 3919 5 1 1 0 7 1.1 20 18 1.11 107 178 218 1 n n n n
90 krishnamurthy 60 m 1800 6 1 0 0 46 163 17.3 7.2 4.1 3 1.6 20 18 1.11 93 190 310 154 n n n 6mm 12mm
91 saroja 65 f 4613 7 18 15 1.20 124 132 231 194 n n
92 palanisamy 70 m 7823 8 1 1 0 6.3 4.1 2.1 47 34 1.38 118 188 n n
93 kannama 60 f 3541 8 0 1 0 64 165 23.5 7.1 4.4 0.9 19 17 1.12 196 140 180 181 n n
94 selvamani 50 f 4553 8 1 1 0 7.3 4.3 3 0.7 28 25 1.12 189 140 235 168 n n
95 jayalakshmi 55 f 4202 10 1 1 0 6.2 3.8 2.4 0.6 18 12 1.50 114 163 n n
96 muthulakshmy 40 f 5931 10 1 0 0 60 157 24.3 19 1i9 1.00 98 102 176 191 1 n n normal normal
97 sundarambal 63 f 8655 10 7 4 31 27 1.08 86 76 143 201 1 n n n
98 lilly 65 f 6712 10 0 0 0 65 158 20.0 7.2 4 3.2 0.8 18 15 1.08 117 156 213 175 1 n n normal normal
99 vijaya 36 f 1581 10 1 0 0 61 154 25.7 7.5 4.4 3.1 0.6 21 17 1.24 77 130 230 194 2 e n normal norml
100 angathal 60 f 318 10 1 0 1 19 17 1.12 86 123 187 n
101 paramaswaran 67 m 403 10 1 1 0 55 175 18.0 7.6 4.2 3.4 1.1 21 17 1.24 80 210 230 221 n n
102 mariammal 45 f 7124 10 1 0 0 60 155 25.0 7.2 4.5 2.7 0.5 12 10 1.20 139 90 140 145 1 n n normal n
103 banu 46 f 1551 10 1 0 0 6.9 4.5 2.4 1 16 14 1.14 99 140 190 174 n
104 hrudiya mary 67 f 6138 10 1 0 0 58 154 24.5 6.9 4.1 2.8 0.8 17 12 1.42 91 178
105 devarajan 61 m 2949 10 1 1 0 7.5 1.5 30 28 1.07 57 235 n n n n n
106 saraswathy 67 f 1181 11 1 1 0 7.1 3.8 1.1 22 18 1.22 83 158 n n
107 vembudurai 69 m 981 11 1 1 0 77 163 29.0 7.3 4.3 3 0.9 18 12 1.50 71 201 n n
108 ramaraj 52 m 172 13 1 0 0 65 168 23.0 6.8 4.1 2.7 0.8 17 15 1.13 79 120 180 211 n
109 sublakshmi 63 f 2390 15 0 0 0 6.9 3.7 0.6 19 17 1.12 103 196
110 rajeshwari 53 f 2586 15 1 0 0 64 153 27.3 6.5 0.9 28 24 1.17 140 211 n n n normal n
111 thyagarajan 64 m 4302 15 1 0 0 74 173 24.7 7.4 4.2 3.2 1 22 18 1.22 153 90 250 154 n n n normal n
112 savithri 55 f 2345 15 1 1 0 55 155 22.9 7.1 4.2 2.9 0.5 19 17 1.12 128 120 140 173
113 vijayarani 55 f 1635 17 1 0 0 75 163 28.2 7.1 3.9 3.2 1.1 27 18 1.50 114 220 240 176 n n n n n
114 kuppusamy 78 m 2545 20 0 2 0 52 165 19.1 7.6 4.7 2.9 0.8 24 21 1.14 169 130 240 201 n n n n n
115 latheef 70 m 760 22 1 1 0 49 165 18.0 6.8 4 2.8 0.8 19 16 1.19 67 90 110 185 n n n n n
116 pankakshi 75 f 7653 22 1 1 0 42 153 18.0 6.1 4 2 1 21 18 1.10 88 98 132 165 n n n n n
117 mehurnisa 56 f 2148 23 1 0 0 53 146 24.9 7.2 4 3.2 0.7 21 19 1.11 106 230 280 165
118 rani 51 f 3985 26 1 1 0 48 148 21.0 7.1 4 3.1 0.8 24 20 1.20 105 180 125 227 1 n n n n
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STUDY OF CLINICAL, BIOCHEMICAL,SONOLOGICAL 
PROFILE OF HEPATIC STATUS IN TYPE 2 DIABETES 
MELLITUS IN TERTIARY CARE SETTING 
 
PROFORMA FOR DATA COLLECTION 
CASE NO: ________ NAME: _____________________  HOSP NO:_______________ 
AGE:______ 
 
                                    SEX:______                       DURATION OF DM2 :___________ 
SYMPTOMS_ 
H/O PRESENT ILLNESS 
           H/O FATIGE 
            H/O ABDOMINAL DISCOMFORT 
           H/O  GENERALISED SWELLING 
PAST HISTORY 
H/O DIABETES ______H/O HYPERTENSION__________ 
ON EXAMINATION 
HEIGHT:_______-WEIGHT;____________BMI:___________ 
PERIPHERAL PULSES_____________ BP___________- 
SYSTEMIC EXAMINATION 
ABDOMEN 
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LABORATORY EXAMINATION 
BLOOD 
LIVER FUNCTION TEST   
SGOT:  SGPT:  ALP:  T.BIL:          TOTA PROT:         ALB;         GLOB:     
 
LIPID PROFILE 
          CHOL:               S. URIC ACID 
BLOOD SUGAR 
           FASTING 
           POST PRANDIAL   
 
ULTRASONOGRAM 
LIVER SIZE 
ECHOTEXTURE ______GRADE 1 
                                     GRADE 2 
                                      GRADE 3 
BILIARY SYSTEM 
PORAL VEIN 
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NAFLD --- Non alcoholic fatty liver 
NASH------Non alcoholic steato hepatitis 
DM --------Diabetes  mellitus 
T CHOL----Total cholesterol 
TG ----------Triglycerides 
AST ---------Aspartate transaminase 
ALT  --------Alanine transaminase 
ALP        ----Alkaline phosphatase 
STP ---------Serum total protein 
HCC ---------Hepatocellular carcinoma 
MS -----------Metabolic syndrome 
HBV  ---------Hepatitis B virus  
HCV ---------Hepatitis C virus 
BMI   --------Body mass index 
OHA    --------Oral hypoglycemic agents  
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